Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210988 | 1.00 | RET (0.37) | RETIRAK1ACVR2ATGFBR2GPR119 | |
| SCHEMBL23211121 | 0.81 | PRKAB2 (0.32) | RETTTK | |
| SCHEMBL29907098 | 0.81 | PRKAB2 (0.32) | RETTTK | |
| SCHEMBL29907124 | 0.78 | TTK (0.40) | RETACVR2ATGFBR2GPR119TTK | |
| SCHEMBL23210931 | 0.78 | TTK (0.40) | RETACVR2ATGFBR2GPR119TTK | |
| SCHEMBL23211115 | 0.78 | TTK (0.41) | RETTTK | |
| SCHEMBL30308777 | 0.78 | TTK (0.41) | RETTTK | |
| SCHEMBL23211008 | 0.78 | TTK (0.38) | RETTTK | |
| SCHEMBL23211112 | 0.78 | TTK (0.41) | RETTTK | |
| SCHEMBL29907183 | 0.78 | TTK (0.41) | RETTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |